Literature DB >> 20478485

Targets for current pharmacologic therapy in cholesterol gallstone disease.

Agostino Di Ciaula1, David Q H Wang, Helen H Wang, Leonilde Bonfrate, Piero Portincasa.   

Abstract

Gallstone disease is a frequent condition throughout the world and, cholesterol stones are the most frequent form in Western countries. The standard treatment of symptomatic gallstone subjects is laparoscopic cholecystectomy. The selection of patients amenable for nonsurgical, medical therapy is of key importance; a careful analysis should consider the natural history of the disease and the overall costs of therapy. Only patients with mild symptoms and small, uncalcified cholesterol gallstones in a functioning gallbladder with a patent cystic duct are considered for oral litholysis by hydrophilic ursodeoxycholic acid, in the hope of achieving cholesterol desaturation of bile and progressive stone dissolution. Recent studies have raised the possibility that cholesterol-lowering agents that inhibit hepatic cholesterol synthesis (statins) or intestinal cholesterol absorption (ezetimibe), or drugs acting on specific nuclear receptors involved in cholesterol and bile acid homeostasis, may offer, alone or in combination, additional medical therapeutic tools for treating cholesterol gallstones. Recent perspectives on medical treatment of cholesterol gallstone disease are discussed in this article. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20478485      PMCID: PMC2915454          DOI: 10.1016/j.gtc.2010.02.005

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  163 in total

Review 1.  The liver X receptor gene team: potential new players in atherosclerosis.

Authors:  Joyce J Repa; David J Mangelsdorf
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

2.  Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption.

Authors:  Scott W Altmann; Harry R Davis; Li-Ji Zhu; Xiaorui Yao; Lizbeth M Hoos; Glen Tetzloff; Sai Prasad N Iyer; Maureen Maguire; Andrei Golovko; Ming Zeng; Luquan Wang; Nicholas Murgolo; Michael P Graziano
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

Review 3.  Measurements of gallbladder motor function by ultrasonography: towards standardization.

Authors:  P Portincasa; A Moschetta; A Colecchia; D Festi; G Palasciano
Journal:  Dig Liver Dis       Date:  2003-07       Impact factor: 4.088

Review 4.  Smooth muscle function and dysfunction in gallbladder disease.

Authors:  Piero Portincasa; Agostino Di Ciaula; Gerard P vanBerge-Henegouwen
Journal:  Curr Gastroenterol Rep       Date:  2004-04

Review 5.  Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes.

Authors:  David Q-H Wang; Nezam H Afdhal
Journal:  Curr Gastroenterol Rep       Date:  2004-04

6.  The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model.

Authors:  Kurt G Davis; Thomas M Wertin; John P Schriver
Journal:  Obes Surg       Date:  2003-12       Impact factor: 4.129

7.  Hydrophilic but not hydrophobic bile acids prevent gallbladder muscle dysfunction in acute cholecystitis.

Authors:  Zuo-Liang Xiao; Piero Biancani; Martin C Carey; Jose Behar
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

8.  Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse.

Authors:  David Q-H Wang; Susumu Tazuma; David E Cohen; Martin C Carey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-05-14       Impact factor: 4.052

9.  Prospective study of abdominal adiposity and gallstone disease in US men.

Authors:  Chung-Jyi Tsai; Michael F Leitzmann; Walter C Willett; Edward L Giovannucci
Journal:  Am J Clin Nutr       Date:  2004-07       Impact factor: 7.045

10.  Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.

Authors:  Yaping Liu; Jane Binz; Mary Jo Numerick; Steve Dennis; Guizhen Luo; Bhasha Desai; Kathleen I MacKenzie; Traci A Mansfield; Steven A Kliewer; Bryan Goodwin; Stacey A Jones
Journal:  J Clin Invest       Date:  2003-11-17       Impact factor: 14.808

View more
  15 in total

1.  Effects of sphincter of Oddi motility on the formation of cholesterol gallstones.

Authors:  Zhong-Hou Rong; Hong-Yuan Chen; Xin-Xing Wang; Zhi-Yi Wang; Guo-Zhe Xian; Bang-Zhen Ma; Cheng-Kun Qin; Zhen-Hai Zhang
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

2.  High rates of recurrent biliary tract obstruction in children with sickle cell disease.

Authors:  Martha O Amoako; James F Casella; John J Strouse
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

3.  Helicobacter pylori infection is positively associated with gallstones: a large-scale cross-sectional study in Japan.

Authors:  Yu Takahashi; Nobutake Yamamichi; Takeshi Shimamoto; Satoshi Mochizuki; Mitsuhiro Fujishiro; Chihiro Takeuchi; Yoshiki Sakaguchi; Keiko Niimi; Satoshi Ono; Shinya Kodashima; Toru Mitsushima; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-06-05       Impact factor: 7.527

4.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06

5.  Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease.

Authors:  Ornella de Bari; Brent A Neuschwander-Tetri; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  J Lipids       Date:  2011-11-03

6.  Effect of ursodeoxycholic Acid alone and ursodeoxycholic Acid plus domperidone on radiolucent gallstones and gallbladder contractility in humans.

Authors:  Ilyas Tuncer; Mustafa Harman; Yasar Colak; Ismail Arslan; M Kursad Turkdogan
Journal:  Gastroenterol Res Pract       Date:  2012-05-07       Impact factor: 2.260

Review 7.  A novel therapeutic effect of statins on nephrogenic diabetes insipidus.

Authors:  Leonilde Bonfrate; Giuseppe Procino; David Q-H Wang; Maria Svelto; Piero Portincasa
Journal:  J Cell Mol Med       Date:  2015-01-16       Impact factor: 5.310

Review 8.  Risk Factors for Cholelithiasis.

Authors:  Mila Pak; Glenda Lindseth
Journal:  Gastroenterol Nurs       Date:  2016 Jul-Aug       Impact factor: 0.978

Review 9.  Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.

Authors:  Magd A Kotb
Journal:  Int J Mol Sci       Date:  2012-07-17       Impact factor: 6.208

10.  Antilithiasic and hypolipidaemic effects of Raphanus sativus L. var. niger on mice fed with a lithogenic diet.

Authors:  Ibrahim Guillermo Castro-Torres; Elia Brosla Naranjo-Rodríguez; Miguel Ángel Domínguez-Ortíz; Janeth Gallegos-Estudillo; Margarita Virginia Saavedra-Vélez
Journal:  J Biomed Biotechnol       Date:  2012-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.